Targeting intracellular signaling as an antiviral strategy: aerosolized LASAG for the treatment of influenza in hospitalized patients

Gerhard ScheuchBio-Inhalation GmbH35285Gemuenden/WohraHessenGermany

Sebastian CanisiusVentaleon GmbH35285Gemuenden/WohraHessenGermany

http://orcid.org/0000-0002-2639-1180

Karlheinz NockerVentaleon GmbH35285Gemuenden/WohraHessenGermany

Thomas HofmannAumapharma LLC18901DoylestownPAUSA

Rolf NaumannVentaleon GmbH35285Gemuenden/WohraHessenGermany

Stephan PleschkaInstitute of Medical VirologyJustus Liebig University Giessen35392GiessenHessenGermany

Stephan LudwigInstitute of Virology (IVM)Westfaelische Wilhelms-University Muenster48149MuensterNorth Rhine-WestphaliaGermany

Tobias WeltePneumology ClinicMedical University Hannover30625HannoverLower SaxonyGermany

Oliver PlanzInterfaculty Institute for Cell Biology, Department of ImmunologyEberhard Karls Tuebingen University72076TuebingenBaden-WürttembergGermanyCorrespondence[email protected]

show all

Targeting intracellular signaling as an antiviral strategy: aerosolized LASAG for the treatment of influenza in hospitalized patients

Supplementary Figure S1

Supplementary Table 1

Supplementary Figure 1 legend

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Targeting intracellular signaling as an antiviral strategy: aerosolized LASAG for the treatment of influenza in hospitalized patients

Supplementary Figure S1

Supplementary Table 1

Supplementary Figure 1 legend

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date